TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05445648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral resection of bladder tumor
Description: After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.
Study: NCT05127616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Contact-Cognitive Behavior Therapy
Description: This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education/Support
Description: This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
Study: NCT06520020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (Tc-SCS)
Description: This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Spinal Cord Stimulation (Tc-SCS)
Description: This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (Tc-SCS)
Description: This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.
Study: NCT06501391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-L1/PD-1 inhibitor and chemotherapy
Description: Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1/PD-1 inhibitor and chemotherapy
Description: Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT or WBRT
Description: Stable brain metastases (BM) patients in this arm will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
Study: NCT04762979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 300mg, PO, days 1-28 of each cycle.
Study: NCT06244277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suanzaoren Decoction and Huanglian Wendan Decoction
Description: Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem 10Mg Tab 10mg tablet once daily
Study: NCT04932629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo cultivated Allogeneic limbal stromal stem cells
Description: n this prospective intervention study patients with unilateral superficial corneal scars will undergo a surgical procedure and in the second procedure, the eligible patients will undergo corneal transplant surgery, when the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 0.5x10\*6 cells/µl diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the cornea at the end of the procedure. The patient will receive topical antibiotic and steroid eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography will be done at Day 1, Day 7, Day 30, Day 90, Day 180 and Day 360 and 720 Days post-surgery
Study: NCT04701684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct to Angio Suite (DTAS) Philips' CBCT triage
Description: Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT/MR triage
Description: First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.
Study: NCT05760001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Financial well-being interventions:~• Tax preparation; access to public benefits; financial counseling and microgrants~Place-based interventions:~• Vacant lot greening; abandoned house remediation; trash cleanup; tree planting
Study: NCT05432076

Intervention type: DEVICE
Intervention: Sleep Band and White Noise
Description: Not taking any sedative or anesthetic drug in the last 12 hours (Such duration of action) An average of 12 hours of sleepiness at the patient's departure and travel hindrance will.)~* Being extubated~* A Glasgow coma scale of 15 (to be investigated by the Glasgow coma scale).~* Baby dreams of boredom~* Besides pain (to the Wong Baker Face Scale used in the Pediatric Intensive Care Unit) evaluation).
Study: NCT04762979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg, IM, once monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: Aromatase Inhibitor, administered per standard of care
Study: NCT05269446

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention (PCI)
Description: A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
Study: NCT06592664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching LSTA1
Description: Placebo given as a slow IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 given as a slow IV push over 1 minute when standard treatment(s) are given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching LSTA1
Description: Placebo given as an IV infusion over 4 hours when standard treatment(s) are given
Study: NCT06662227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single dose injection of certain dose of UWD-19
Description: Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-19 cells
Study: NCT05320731

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization with lidocaine
Description: A face mask nebulizer with oxygen flow rate of 8 L/min will be used to deliver 10 mL of 2% lidocaine. Patients will be encouraged to inhale deeply to facilitate entrainment of nebulized LA into their airway. Adequate topical anesthesia will be confirmed by heaviness or numbness of the tongue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atomization with lidocaine
Description: A simple atomization device as a modification of the McKenzie technique will be used. One end of oxygen bubble tubing will be cut to fit into the barrel of 1 mL syringe and attached to one connector of a 3-way tap. A 10-mL syringe filled with 2% lidocaine will be attached to the other connector of the 3-way tap. A 6 Fr suction catheter, with its colored end cut and its distal blind end cut open, will be attached to oxygen bubble tubing via the male Luer connector of the 3-way tap. The other end of bubble tubing will be then attached to an oxygen source turned on to deliver a flow of 6 L/min. As LA is slowly atomized as a jet-like spray, the catheter will be directed towards the soft palate and posterior pharynx in a controlled fashion during patients' inspiration to topicalize the airway. Patients will be asked to take full vital capacity breaths of atomized LA contained oxygen. Adequate topical anesthesia will be confirmed by tongue heaviness or numbness
Study: NCT05269446

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention (PCI)
Description: A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA

Intervention type: DEVICE
Intervention: total body PET/CT scan
Description: all participants will receive a total-body PET/CT scan (uExplorer) after enrolment

Intervention type: DEVICE
Intervention: total body PET/CT scan
Description: all participants will receive a total-body PET/CT scan (uExplorer) after enrolment

Intervention type: DEVICE
Intervention: total body PET/CT scan
Description: all participants will receive a total-body PET/CT scan (uExplorer) after enrolment

Intervention type: PROCEDURE
Intervention: Coronary Angiography (CAG)
Description: A procedure that uses X-ray imaging to visualize coronary arteries.

Intervention type: PROCEDURE
Intervention: Coronary Angiography (CAG)
Description: A procedure that uses X-ray imaging to visualize coronary arteries.
Study: NCT06614933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic transcutaneous auricular vagus nerve stimulation
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic transcutaneous auricular vagus nerve stimulation
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic transcutaneous auricular vagus nerve stimulation
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monophasic transcutaneous auricular vagus nerve stimulation
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
Study: NCT06674226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: 0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
Study: NCT05016505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction (relocation and reduction of personal smoking) and cessation
Description: Individual-level. Peer educator to provide reduction/cessation and/or relocation support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction (relocation and reduction of personal smoking) and cessation
Description: Individual-level. Peer educator to provide reduction/cessation and/or relocation support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Endorsement
Description: Building-level. Peer educator to conduct building-level sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Endorsement
Description: Building-level. Peer educator to conduct building-level sessions.
Study: NCT05269446

Intervention type: PROCEDURE
Intervention: Coronary Angiography (CAG)
Description: A procedure that uses X-ray imaging to visualize coronary arteries.

Intervention type: DRUG
Intervention: TSPO injection
Description: Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer

Intervention type: DRUG
Intervention: TSPO injection
Description: Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer

Intervention type: DRUG
Intervention: TSPO injection
Description: Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
Study: NCT05704166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone/Placebo
Description: Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone/Placebo
Description: Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
Study: NCT06399614

Intervention type: OTHER
Intervention: Occupational Therapy-led Hand Therapy Service
Description: Types of interventions provided by the therapist will include splinting, targeted exercises and activities, occupation-based intervention, edema management, scar management; desensitisation, functional tasks completion, and education. All interventions provided are within occupational therapists' scope of practice and are evidence based. Number of treatment sessions will be individualised to the patient and guided by stages of recovery.

Intervention type: OTHER
Intervention: Care as usual
Description: Care as usual group: Participants attending an emergency department of injury unit, do not have access to occupational therapy services and will undergo 'care as usual' in line with the services\&#39; protocols and procedures. Care as usual involves standard nursing and medical care and may include: wound care, use of 'off the shelf' orthosis, education, and onward referral to other healthcare professionals.
Study: NCT05244317

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cast
Description: the cast of the upper limb from just below elbow joint to the knuckle of fingers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: splint
Description: Removable splint
Study: NCT06710834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoadsorption cartridge
Description: HA 130 cartridge

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: Postdilutional hemodiafiltration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Description: Postdilutional hemodiafiltration
Study: NCT06733402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene Cream 0.005%
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Study: NCT06731920

Intervention type: DIAGNOSTIC_TEST
Intervention: cervical medial branch block
Description: ultrasound-guided cervical medial branch block with fluoroscopic control and digital subtraction angiography
Study: NCT06733324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCERTS (Social Communication, Emotional Regulation, Transactional Support)
Description: The SCERTS (Social Communication, Emotional Regulation, and Transactional Support) intervention is a comprehensive, multidisciplinary approach specifically tailored to address the unique needs of children with Autism Spectrum Disorder (ASD) aged 3-6 years. Unlike traditional behavioral therapies such as Applied Behavior Analysis (ABA), SCERTS emphasizes a developmental framework, focusing on enhancing social communication, emotional regulation, and environmental support. It incorporates family involvement and integrates strategies into naturalistic settings, ensuring skill generalization across home, school, and community environments.~This intervention is distinguished by its individualized goals based on each child's developmental profile and its emphasis on fostering meaningful interactions rather than relying on compliance-based methods. SCERTS also incorporates transactional supports, such as modifying the physical and social environment to promote engagement and reduce stress, w

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Treatment, Speech Therapy
Description: The control group will be the treatment as usual group receiving conventional behavior therapy and speech therapy
Study: NCT06733844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly iron folic acid supplementations
Description: In the intervention arm, adolescent girls will receive weekly iron and folic acid supplements (WIFAS), nutrition education, and group counseling sessions. WIFAS will be delivered quarterly, with each girl consuming one supplement at the facilitation center and the remaining 12 at home, once a week. The supplements contain 60mg of iron and 2.8mg of folic acid. A quarterly cash transfer of PKR 1,000 will be given to the mother, conditional on the girl's WIFAS consumption and attendance at the quarterly education and counseling sessions. The girl will report her supplement intake at each visit and receive 13 more supplements. The intervention will last 18 months.
Study: NCT06733558

Intervention type: PROCEDURE
Intervention: Electroconvulsive Therapy
Description: Electroconvulsive therapy (ECT) is a medical treatment that uses controlled electrical stimulation to induce a brief, generalized seizure in the brain. This intervention is performed under general anesthesia with muscle relaxants to ensure patient comfort and safety. ECT is typically used to treat severe depression, bipolar disorder, and other mental health conditions when other treatments, such as medication and psychotherapy, have not been effective.